News
Videos
Conferences
Events
Resources
Subscribe

|Articles|April 22, 2015

Dr. Primo Lara Discusses Emerging Therapies in Kidney Cancer

Primo Neary Lara Jr., associate director of Translational Research at the UC Davis Comprehensive Cancer Center, discusses emerging therapies for patients with kidney cancer.

Primo Neary Lara Jr., associate director of Translational Research and co-leader of the Cancer Therapeutics Program at UC Davis Comprehensive Cancer Center, discusses emerging therapies for patients with kidney cancer.

Newsletter

Stay up to date on cancer updates, research and education

Related Content

Dr. Suneel Kamath addresses patient concerns on the topic of clinical trial participation in the gastrointestinal cancer treatment space.

Why Clinical Trials May Offer More for Patients With GI Cancers

ByDr. Suneel Kamath

February 2nd 2026

Dr. Kathie-Ann Joseph

Breaking Down Surgical Advancements for Those With Breast Cancer

ByDr. Kathie-Ann Joseph

February 2nd 2026

Dr. Pablo Prichard

What MRD Testing Can Mean for Patients With Breast Cancer and Survivors

ByDr. Pablo Prichard

February 1st 2026

Image of Dr. Obeid.

Risk Assessment Remains Vital for Patients Even After Cancer Diagnosis

ByDr. Elias Obeid

January 30th 2026

Dr. Suneel Kamath discusses the importance of biomarker-driven approaches in cancer care following the 2026 ASCO GI Symposium.

Expert insights into Biomarker-Driven Care and Emerging Targets in GI Cancer

ByDr. Suneel Kamath

January 29th 2026

Trending on CURE

Biotin Supplements May Complicate Cancer Care, Research Shows

Biotin, Lab Interference and Safer Options for Cancer-Related Hair Loss

What MRD Testing Can Mean for Patients With Breast Cancer and Survivors

Erleada Shows Survival Advantage in Real-World Study of Metastatic Prostate Cancer

Most Patients With HER2+ Breast Cancer Miss Standard Treatment, Study Shows